-
公开(公告)号：US20180282304A1
公开(公告)日：2018-10-04
申请号：US16008419
申请日：2018-06-14
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Göran Mattias Wennerstål , James Robert Blinn , Neelu Kaila , James Richard Kiefer, JR. , Scot Richard Mente , Ravi G. Kurumbail , Marvin Jay Meyers , Atli Thorarensen , Li Xing , Christoph Wolfgang Zapf , Edouard Zamaratski , Andrew Christopher Flick , Peter Jones
IPC: C07D401/14 , C07D403/04 , C07D413/14 , A61K31/454 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/5355 , C07D401/04 , C07D407/14 , C07D413/04 , C07D405/14 , C07D487/04 , C07D471/04 , C07D417/14
Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
-
公开(公告)号：US20180148420A1
公开(公告)日：2018-05-31
申请号：US15574625
申请日：2016-05-16
Applicant: Pfizer Inc.
Inventor： Agustin Casimiro-Garcia , Jeffrey Scott Condon , Andrew Christopher Flick , Ariamala Gopalsamy , Steven J. Kirincich , John Paul Mathias , Joseph Walter Strobach , Jason Shaoyun Xiang , Li Huang Xing , Xiaolun Wang
IPC: C07D239/42 , A61P1/00 , A61P1/04 , A61P35/00 , C07D401/12 , C07D403/12 , C07D405/10
CPC classification number: C07D239/42 , A61K31/505 , A61P1/00 , A61P1/04 , A61P35/00 , C07D239/28 , C07D241/14 , C07D401/12 , C07D403/12 , C07D405/10
Abstract: Compounds, pharmaceutically acceptable salts thereof are disclosed wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US20180086736A1
公开(公告)日：2018-03-29
申请号：US15834545
申请日：2017-12-07
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Göran Mattias Wennerstål , James Robert Blinn , Neelu Kaila , James Richard Kiefer, JR. , Scot Richard Mente , Ravi G. Kurumbail , Marvin Jay Meyers , Atli Thorarensen , Li Xing , Christoph Wolfgang Zapf , Edouard Zamaratski , Andrew Christopher Flick , Peter Jones
IPC: C07D401/14 , C07D487/04 , C07D413/14 , A61K31/454 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/5355 , C07D401/04 , C07D407/14 , C07D413/04 , C07D405/14 , C07D403/04 , C07D471/04 , C07D417/14
CPC classification number: C07D401/14 , A61K31/454 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/5355 , C07D401/04 , C07D403/04 , C07D405/14 , C07D407/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , Y02A50/406 , A61K2300/00
Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
-
14.发明授权公开(公告)号：US09670201B2
公开(公告)日：2017-06-06
申请号：US14864840
申请日：2015-09-24
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Göran Mattias Wennerstål , Li Xing , Edouard Zamaratski , Liying Zhang
IPC: C07D401/02 , C07D401/10 , A61K31/437 , A61K31/4353 , C07D471/04 , C07D401/14
CPC classification number: C07D471/04 , C07D401/14
Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
-
公开(公告)号：US10975065B2
公开(公告)日：2021-04-13
申请号：US16576997
申请日：2019-09-20
Applicant: Pfizer Inc.
Inventor： Brian Stephen Gerstenberger , Andrew Christopher Flick , Vincent Michael Lombardo , James John Mousseau , Philippe Marcel Nuhant , Ralph Pelton Robinson, Jr. , Mark Edward Schnute , Daniel Wei-Shung Kung , Daniel Copley Schmitt , Atli Thorarensen , John Isidro Trujillo , Rayomand Jal Unwalla , Huixian Wu
IPC: C07D413/14 , A61P29/00 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07F9/6558
Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
-
Patent Agency Ranking
16.发明申请公开(公告)号：US20200095239A1
公开(公告)日：2020-03-26
申请号：US16576997
申请日：2019-09-20
Applicant: Pfizer Inc.
Inventor： Brian Stephen Gerstenberger , Andrew Christopher Flick , Vincent Michael Lombardo , James John Mousseau , Philippe Marcel Nuhant , Ralph Pelton Robinson, JR. , Mark Edward Schnute , Daniel Wei-Shung Kung , Daniel Copley Schmitt , Atli Thorarensen , John Isidro Trujillo , Rayomand Jal Unwalla , Huixian Wu
IPC: C07D413/14 , C07D401/12 , C07D401/14 , C07D417/12 , C07D413/12 , C07D405/14 , C07D417/14 , C07F9/6558 , A61P29/00
Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
-
17.发明申请公开(公告)号：US20190387710A1
公开(公告)日：2019-12-26
申请号：US16563022
申请日：2019-09-06
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Goran Mattias Wennerstal , Li Xing , Edouard Zamaratski , Liying Zhang , Rayomand Jal Unwalla
IPC: A01K5/01 , B65D25/18 , B65D25/04 , B65D1/36 , B65D1/34 , A01K7/00 , B65D77/20 , A23K20/00 , A23K50/48 , C07D471/04 , C07D401/14
Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
-
公开(公告)号：US10336748B2
公开(公告)日：2019-07-02
申请号：US15546887
申请日：2016-01-29
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Goran Mattias Wennerstal , Li Xing , Edouard Zamaratski , Liying Zhang , Rayomand J. Unwalla
IPC: C07D471/04
Abstract: The present invention provides methoxy-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
-
19.发明申请公开(公告)号：US20190150401A1
公开(公告)日：2019-05-23
申请号：US16268857
申请日：2019-02-06
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Goran Mattias Wennerstal , Li Xing , Edouard Zamaratski , Liying Zhang , Rayomand Jal Unwalla
IPC: A01K5/01 , B65D77/20 , B65D25/04 , B65D1/34 , A01K7/00 , B65D25/18 , A23K20/00 , A23K50/48 , B65D1/36
CPC classification number: A01K5/0121 , A01K7/00 , A23K20/00 , A23K50/48 , B65D1/34 , B65D1/36 , B65D25/04 , B65D25/18 , B65D77/2024 , B65D85/70 , B65D2577/205 , C07D401/14 , C07D471/04
Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
-
20.发明授权公开(公告)号：US10227346B2
公开(公告)日：2019-03-12
申请号：US15889296
申请日：2018-02-06
Applicant: Pfizer Inc.
Inventor： Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Goran Mattias Wennerstal , Li Xing , Edouard Zamaratski , Liying Zhang , Rayomand Jal Unwalla
IPC: A61K31/437 , A61K31/4353 , C07D471/04 , C07D401/14
Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.039 seconds)
